Survivorship experience for patients (pts) with metastatic melanoma (MM) on long-term targeted therapy (TT).

9556 Background: TT has improved survival for pts with MM. The lived experience for long-term responders remains under-studied. We characterised pt issues using a cross-sectional survey. Methods: Eligible pts had MM, aged > 18, ≥ 6 months post initiation of TT, and had a complete response. A 72-item survey including items from validated measures and custom questions covering physical and psychological effects, impact on lifestyle, access to information, satisfaction with care, and availability of support was administered. Impact of treatment duration (≤12 / > 12 months) on pt experience was assessed. Results: 36/42 (86%) pts responded from Aug-Dec 2017: median age 59 (range 30-84); 18 (50%) male; 21 (58%) had M1c disease; 34 (94%) were receiving TT as 1st line therapy. The majority (31, 86%) were still on treatment; most (22, 74%) had been on treatment for > 12 months. Long-term toxicities including fatigue (33, 92%), dry/itchy skin (25, 69%) and arthralgias (23, 64%) were common. Typical acute toxicities, such as fevers, rashes and gastrointestinal toxicities, were minimal. Psychological morbidity was high, including fear of cancer recurrence (31, 86%), concern regarding long-term toxicities (30, 83%), anxiety awaiting results (29, 81%), concern regarding ongoing sun exposure (28, 78%) and fear of death (26, 72%). The prevalence of both physical and psychological issues was higher among pts on treatment > 12 months, and persisted in 5 (14%) who ceased treatment. Patients reported difficulties with finances (19, 53%), undertaking recreational activities (23, 64%), and performing domestic tasks (14, 39%). Most would value screening for skin cancers (35, 97%), for other cancers (34, 94%), and a survivorship care plan (SCP) to guide management (34, 94%). Conclusions: Physical, psychological and functional issues exist in long-term responders to TT. These issues may increase with increasing duration on treatment. Pts may benefit from ongoing toxicity management, tailored psychological support and an SCP.